EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis

Sudipto Mukherjee, Cherrishe Brown-Bickerstaff, Angelica Falkenstein, Adeola Y Makinde, Emily Bland, JaLyna Laney, Marné Garretson, David Huggar, Ali McBride

HemaSphere · 2024-01 · 8 (1)

DOI: 10.1002/hem3.38 ↗

At a glance

Journal article in HemaSphere, published online on 2024-01-30. Written by Sudipto Mukherjee and 8 co-authors. Institution: Department of Hematology and Medical Oncology Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA. Cited 10 times so far (Crossref); 12 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Bristol-Myers Squibb.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Anemia is the most common cytopenia associated with lower-risk myelodysplastic syndromes (LR-MDS), resulting in between 50% and 90% of patients requiring red blood cell (RBC) transfusions.1, 2 However, severe anemia and transfusion dependency have been associated with shorter overall survival.3 The real-world clinical benefit of available treatments for myelodysplastic syndromes (MDS) ranks among the lowest of all hematologic malignancies, especially when compared with findings from clinical trials,4, 5 potentially in part due to the variability between trial participants and the general patient populations.6, 7 Luspatercept is a first-in-class erythroid maturation agent and recombinant transforming growth factor β superfamily ligand-binding fusion protein that works to restore erythropoiesis by increasing the number and improving the quality of mature RBCs.8 Based on the results from the MEDALIST trial (NCT02631070)9 and the recent COMMANDS trial (NCT03682536),10 luspatercept is approved by the US Food and Drug Administration (FDA) for the treatment of anemia with or without prior erythropoiesis-stimulating agent (ESA) use in adult patients with very low- to intermediate-risk MDS who may require regular RBC transfusions.11, 12 In this study, we collected real-world data from patients with LR-MDS treated with luspatercept in the United States and analyzed treatment patterns and clinical outcomes. In this retrospective medical chart review, we used de-identified, patient-level data abstracted from patients' electronic medical records into an electronic case report form by physicians recruited from the Cardinal Health Oncology Provider Extended Network (OPEN), a community of >800 private practice and hospital-based oncologists/hematologists across the United States; and all study procedures were conducted in accordance with the Declaration of Helsinki. Eligible patients were ≥18 years of age at initiation of luspatercept treatment for LR-MDS, were diagnosed with LR-MDS (International Prognostic Scoring System [IPSS] score of Low or Intermediate-1 risk and/or a Revised IPSS [IPSS-R] score of Very low, Low, or Intermediate risk) confirmed by bone marrow biopsy on or after January 1, 2015, and had ≥12 weeks of luspatercept treatment (unless the patient died ˂12 weeks following initiation). Data were collected between May 31, 2022 and July 12, 2022. The primary outcome was the achievement of transfusion independence (TI) or maintenance of non-transfusion dependent (NTD) status for ≥8 weeks during the first 24 weeks (weeks 1–24) of luspatercept treatment. Key secondary outcomes were achievement of modified hematologic improvement-erythroid (mHI-E, defined as a reduction in RBC and/or platelet sessions of ≥4 sessions in a ≥8-week period in patients with a baseline transfusion burden [TB] of ≥4 RBC and/or platelet sessions, or as an increase in hemoglobin level of ≥1.5 g/dL in a ≥8-week period in patients with a baseline TB of

Authors and institutions

  • Department of Hematology and Medical Oncology Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA.
  • Formerly of Cardinal Health Dublin Ohio USA.
  • Bristol Myers Squibb Princeton New Jersey USA.
  • Cardinal Health Dublin Ohio USA.

Funding

  • Bristol-Myers Squibb

Cite

APA

Mukherjee, S., Brown-Bickerstaff, C., Falkenstein, A., Makinde, A. Y., Bland, E., Laney, J., Garretson, M., Huggar, D., & McBride, A. (2024). Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis. HemaSphere, 8(1). https://doi.org/10.1002/hem3.38

Vancouver

Mukherjee S, Brown-Bickerstaff C, Falkenstein A, Makinde AY, Bland E, Laney J, et al. Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis. HemaSphere. 2024;8(1). doi:10.1002/hem3.38

BibTeX
@article{Mukherjee2024,
  author = {Mukherjee, Sudipto and Brown-Bickerstaff, Cherrishe and Falkenstein, Angelica and Makinde, Adeola Y and Bland, Emily and Laney, JaLyna and Garretson, Marné and Huggar, David and McBride, Ali},
  title = {Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis},
  journal = {HemaSphere},
  year = {2024},
  volume = {8},
  number = {1},
  doi = {10.1002/hem3.38}
}
Start for free →